乾癬性関節炎（PsA）：疫学予測（～2033年）

2023年、主要7市場全体のPsA発症者は4万5,580人でした。これらの発症者の大部分を米国が占め、18歳以上の男女合計で2万2,124人でした。日本は2023年のPsA発症者のうち最小の341人を占めました。2023年、主要7市場全体のPsA有病者は154万7,313人でした。これらの有病者の大部分を米国が占め、18歳以上の男女合計で76万3,439人でした。日本は2023年のPsA有病者のうち最小の1万2,063人を占めました。主要7市場全体のPsA有病者数の成長の主な要因は、PsAの診断率の全体的な増加です。さらに、GlobalDataの疫学者は、主要7市場におけるPsAの発症者数と有病者数の増加は、各市場における人口動態によるものであるとしています。

当レポートでは、主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）における乾癬性関節炎（PsA）について調査分析し、危険因子や併存疾患、過去の疫学的動向に関する情報を提供しています。

目次

第1章 乾癬性関節炎：エグゼクティブサマリー

• カタリスト
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界の過去の動向
• 予測手法
• PsAの疫学的予測（2023年～33年）
  • PsAの発症者数
  • PsAの発症者数：性別
  • PsAの発症者数：年齢別
  • PsAの有病者数
  • PsAの有病者数：性別
  • PsAの有病者数：年齢別
  • 有病者数：タイプ別
  • 有病者数：重症度別
  • 有病者数：合併症別
  • 乾癬を伴うPsAの有病者数
• 議論
  • 疫学的予測の考察
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbidities for PsA
• Table 4: 7MM, diagnosed prevalent cases by severity (N), men and women, ages >=18 years, 2023
• Table 5: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

• Figure 1: 7MM, diagnosed incident cases of PsA (N), men and women, ages >=18 years, 2023 and 2033
• Figure 2: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages >=18 years, 2023 and 2033
• Figure 3: 7MM, diagnosed incidence of PsA (cases per 100,000 population), men and women, ages >=18 years, 2023
• Figure 4: 7MM, diagnosed prevalence of PsA (%), men and women, ages >=18 years, 2023
• Figure 5: 7MM, sources used and not used to forecast the diagnosed incident cases of PsA
• Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of PsA
• Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of PsA by type
• Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PsA with comorbidity
• Figure 9: 7MM, diagnosed incident cases of PsA (N), men and women, ages >=18 years, 2023
• Figure 10: 7MM, diagnosed incident cases of PsA by sex (N), ages >=18 years, 2023
• Figure 11: 7MM, diagnosed incident cases of PsA by age (N), men and women, 2023
• Figure 12: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages >=18 years, 2023
• Figure 13: 7MM, diagnosed prevalent cases of PsA by sex (N), ages >=18 years, 2023
• Figure 14: 7MM, diagnosed prevalent cases of PsA by age (N), men and women, 2023
• Figure 15: 7MM, diagnosed prevalent cases by type (N), men and women, ages >=18 years, 2023
• Figure 16: 7MM, diagnosed prevalent cases by severity (N), men and women, ages >=18 years, 2023
• Figure 17: 7MM, diagnosed prevalent cases of PsA with psoriasis (N), men and women, ages >=18 years

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive and can lead to severe joint damage and disability (Ogdie and Gelfand, 2011). The disease is considered rare in the general population, but PsA affects up to 30% of people with psoriasis (Ogdie and Gelfand, 2011; National Psoriasis Foundation, 2024). It is estimated that more than 85% of PsA cases are preceded by psoriasis, which can vary in form and duration; the remaining PsA cases are diagnosed simultaneously with psoriasis or in the absence of skin disease (Gottlieb et al., 2008; Wilson et al., 2009). PsA is a highly heterogeneous disease that may present with nonspecific symptoms, often making diagnosis difficult (Ogdie and Gelfand, 2011). General symptoms associated with PsA include generalized fatigue, tenderness in tendons, swollen fingers and toes, stiffness and pain in joints, conjunctivitis, and nail changes (National Psoriasis Foundation, 2024). Historically, diagnosing PsA has been difficult due to the limited recognition of the disease and the highly heterogeneous diagnostic criteria. However, the recently developed Classification of Psoriatic Arthritis (CASPAR) criteria have become the most accepted standard for diagnosing PsA.

In 2023, there were 45,580 diagnosed incident cases of PsA across the 7MM. The US accounted for the majority of these cases, with 22,124 diagnosed incident cases of PsA in men and women combined, ages 18 years and older. Japan accounted for the fewest cases in 2023, with 341 diagnosed incident cases of PsA. In 2023, there were 1,547,313 diagnosed prevalent cases of PsA across the 7MM. The US accounted for the majority of these cases, with 763,439 diagnosed prevalent cases of PsA in men and women combined, ages 18 years and older. Japan accounted for the fewest cases in 2023, with 12,063 diagnosed prevalent cases of PsA. Due to the methodology used by GlobalData to obtain primary market research (PMR) data, the main driver of growth in the diagnosed prevalent cases of PsA across the 7MM is the overall increase in the diagnosis rate of PsA. Additionally, GlobalData epidemiologists attribute the increase in the diagnosed incident cases and diagnosed prevalent cases of PsA in the 7MM to population dynamics in each market.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for PsA across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of PsA and a 10-year forecast of diagnosed prevalent cases of PsA segmented by sex and age (beginning at age 18 years and ending at ages 85 years or older) in these markets.
• This report also includes an assessment of PsA severity, an analysis of diagnosed prevalent cases by subtype based on the Moll and Wright Criteria, data on prevalent PsA cases with comorbidities, and a forecast of prevalent PsA cases with psoriasis.
• The epidemiology model will provide additional clinically relevant segmentations, including a forecast for the total prevalent cases (diagnosed and undiagnosed) of PsA.

Reasons to Buy

The Psoriatic arthritis (PsA) epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global PsA market.
• Quantify patient populations in the global PsA market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PsA therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Psoriatic Arthritis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 Forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Diagnosed incident cases of PsA
  • 2.4.4 Diagnosed prevalent cases of PsA
  • 2.4.5 Diagnosed prevalent cases of PsA by type
  • 2.4.6 Diagnosed prevalent cases of PsA by severity
  • 2.4.7 Diagnosed prevalent cases of PsA with comorbidity
  • 2.4.8 Diagnosed prevalent cases of PsA with psoriasis
• 2.5 Epidemiological forecast for PsA (2023-33)
  • 2.5.1 Diagnosed incident cases of PsA
  • 2.5.2 Sex-specific diagnosed incident cases of PsA
  • 2.5.3 Age-specific diagnosed incident cases of PsA
  • 2.5.4 Diagnosed prevalent cases of PsA
  • 2.5.5 Sex-specific diagnosed prevalent cases of PsA
  • 2.5.6 Age-specific diagnosed prevalent cases of PsA
  • 2.5.7 Diagnosed prevalent cases by type
  • 2.5.8 Diagnosed prevalent cases by severity
  • 2.5.9 Diagnosed prevalent cases by comorbidity
  • 2.5.10 Diagnosed prevalent cases of PsA with psoriasis
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 Limitations of the analysis
  • 2.6.3 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - prescriber survey
• 3.3 Primary market research - Key opinion leaders (KOLs) interviewed for this report
  • 3.3.1 KOLs
• 3.4 About the authors
  • 3.4.1 Epidemiologist
  • 3.4.2 Reviewers
  • 3.4.3 Vice President of Disease Intelligence and Epidemiology
  • 3.4.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us